Skip to main content

Peer Review reports

From: Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial

Original Submission
28 Oct 2022 Submitted Original manuscript
28 Nov 2022 Reviewed Reviewer Report
24 Jan 2023 Reviewed Reviewer Report
14 Feb 2023 Author responded Author comments - Haiyan Jia
Resubmission - Version 2
14 Feb 2023 Submitted Manuscript version 2
23 Feb 2023 Reviewed Reviewer Report
4 Mar 2023 Author responded Author comments - Haiyan Jia
Resubmission - Version 3
4 Mar 2023 Submitted Manuscript version 3
Publishing
6 Mar 2023 Editorially accepted
16 Mar 2023 Article published 10.1186/s12916-023-02814-w

You can find further information about peer review here.

Back to article page